Skip to main content
A woman walking confidently down a city street with two tan-colored wolves, one on each side of her, all facing forward. The text next to her reads "For your patients with SSTR+ GEP-NETs, START STRONG WITH LUTATHERA. Lutathera has practice-changing evidence for your patients who are newly diagnosed or at SSA progression. Not an actual patient."

NETTER-2 is a phase 3, randomized, open-label, active comparator, multicenter study of the efficacy of LUTATHERA with 30 mg octreotide LAR (n=151) vs 60 mg octreotide LAR (n=75) in patients with newly diagnosed, well-differentiated, grade 2 or 3 advanced SSTR+ GEP-NETs. The primary end point of the study was centrally assessed PFS. The median PFS in the LUTATHERA arm was 22.8 months (95% CI, 19.4-NE) vs 8.5 months (95% CI, 7.7-13.8) in the control arm.1,4*

NETTER-1 was a pivotal, phase 3, randomized, multicenter, open-label study of LUTATHERA with 30 mg octreotide LAR (n=116) vs 60 mg octreotide LAR (n=113) in patients with locally advanced, inoperable, or metastatic grade 1 or 2 SSTR+ GEP-NETs after progression on an SSA. The primary end point of the study was centrally assessed PFS. The median PFS in the LUTATHERA arm was not reached at primary analysis (95% CI, 18.4-NE) vs 8.5 months (95% CI, 6.0-9.1) in the control arm.2,3,5*

*Defined as the time from randomization to first documented progression (centrally assessed according to RECIST v1.1) or death due to any cause.1

Important Safety Information

WARNINGS AND PRECAUTIONS

  • Radiation Exposure: Treatment with LUTATHERA contributes to a patient’s overall long-term cumulative radiation exposure and is associated with an increased risk for cancer...

Indication

LUTATHERA® (lutetium Lu 177 dotatate) is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND INDICATION
GEP-NET, gastroenteropancreatic neuroendocrine tumor; LAR, long-acting release; NE, not evaluable; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; SSA, somatostatin analog; SSTR+, somatostatin receptor-positive.
 
References: 1. Data on file. Novartis Pharmaceuticals Corp; 2021. 2. Lutathera. Prescribing information. Novartis Pharmaceuticals Corp. 3. Strosberg J, El-Haddad G, Wolin E, et al; for the NETTER-1 trial investigators. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125-135. 4. Data on file. Novartis Pharmaceuticals Corp; 2023. 5. US Food and Drug Administration. FDA approves new treatment for certain digestive tract cancers [press release]. Updated January 26, 2018. Accessed November 30, 2023. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-certain-digestive-tract-cancers